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Summary objective To compare the outcome of treatment of Sudanese kala-azar patients treated under ﬁeld con-
ditions with either branded sodium stibogluconate (SSG) (Pentostam GlaxoWellcome) or generic SSG
(Albert David Ltd, Calcutta, supplied by International Dispensary Association, Amsterdam).
method Randomised comparison. 271 patients were treated with Pentostam and 245 with generic SSG.
results No statistically signiﬁcant differences in cure rate or mortality were detected between Pentostam
and generic SSG. No differences in side-effects between the two drugs were noted. The initial cure rate at the
time of discharge was 93.7 and 97.6%, respectively; the death rate during treatment 5.9 and 2.4%. Six
months follow up was achieved in 88.5% of the discharged patients. Two patients had died in the Pentostam
group and two had died in the generic SSG group, giving a ﬁnal death rate of 7.5 and 3.7%. The number of
relapses in the Pentostam and generic SSG groups were 3 and 1, respectively. The ﬁnal cure rates, calculated
at 6 months after discharge, were 91.3% and 95.9%.
conclusion No difference was observed in the performance of generic SSG compared to Pentostam for the
treatment of visceral leishmaniasis in Sudan. Generic SSG can be routinely and safely used for the treatment
of kala-azar. Generic SSG costs only 1/14 of the price of Pentostam. The use of generic SSG may make treat-
ment of kala-azar affordable for national governments in Africa.
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Introduction
Visceral leishmaniasis (kala-azar) is a fatal disease if not
treated. About 500 000 new cases occur each year (UNDP
et al. 1997), mainly in India. Sudan is another area of con-
cern; precise incidence ﬁgures are not available, but it is esti-
mated that in south Sudan, during the period 1989–94,
100000 people died in a kala-azar epidemic (Seaman et al.
1996a). Since 1988 Médecins Sans Frontières (MSF)-Holland
has treated approximately 40000 kala-azar patients in the
Sudan, initially in Upper Nile and subsequently in the
Gedaref states.
The mainstay of the treatment of kala-azar remain the
pentavalent antimony compounds. In East Africa, Pentostam,
sodium stibogluconate (SSG), produced by GlaxoWellcome
in the UK, is used. High cost (an average of 200 US dollars
per patient), combined with output of the product which is
exceeded at times by demand, make continuity in the supply
of Pentostam uncertain. A cheaper, good quality drug is
needed.
In India, sodium stibogluconate is manufactured by several
companies, and used in large numbers of patients. Some
batches of production have been found to be unexpectedly
toxic (Sundar et al. 1998). Sodium stibogluconate has been
manufactured by Albert David Ltd, Calcutta, for several
decades and sold under the name Sodium Antimony
Gluconate. The difference in name has led to generic SSG
(Albert David) being regarded, erroneously, as a different
drug to sodium stibogluconate. The International Dispensary
Association (IDA, Amsterdam) inspected the manufacturing
process and undertook independent quality testing of generic
SSG (Albert David). Using an ongoing programme of inde-
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pendent quality control, treated IDA provides generic SSG at
around 13 US dollars per patient. Introducing generic SSG for
the treatment of kala-azar in East Africa could make large-
scale production of high-quality SSG available at low cost.
However, MSF recognized that, having used solely Pentostam
for visceral leishmaniasis for 50 years, individuals and insti-
tutions would have conﬁdence in the use of generic SSG only
when it has been carefully evaluated clinically. In a mission
hospital setting, no differences in efﬁcacy and tolerability
between the two drugs were detected in a study of 102 kala-
azar patients (Moore et al. 2000). We compared the efﬁcacy
and toxicity of generic SSG and Pentostam under ﬁeld con-
ditions.
Methods
The study was implemented in the MSF kala-azar treatment
centres Um Kuraa and Kassab in Gedaref state, Sudan. The
centres were established in 1996 and 1998 to treat the large
number of kala-azar patients coming from this highly
endemic focus. The trial was conducted with agreement, and
in co-operation with, regional and federal health authorities
and Sudanese kala-azar experts.
Protocol
Patients, mostly self referred, were seen at the MSF kala-azar
screening centres. The following clinical case deﬁnition was
used: patients with fever for more than two weeks (with ex-
clusion of malaria), in combination with either splenomegaly
or wasting. In cases meeting the case deﬁnition, kala-azar was
conﬁrmed by a $ 1:6400 titre of antibodies against Leish-
mania by the Direct Agglutination Test (and a subsequent
response to antimonial treatment); or by demonstration of
Leishmania on aspirates of spleen or lymph node (WHO
1996). DAT antigen was obtained from the Prince Leopold
Institute of Tropical Medicine, Antwerp, Belgium. The DAT
was standardized with freeze-dried positive sera of known
titre.
In case of a borderline DAT titre of 1:400 to1:6400, aspir-
ation of an inguinal lymph node or spleen was performed. In
acutely ill patients, both DAT and aspiration were performed
on the same day. If the results were negative but the clinical
suspicion of kala-azar remained high, the DAT and/or aspir-
ation were repeated. Giemsa-stained slides were read by MSF
laboratory technicians, stored and checked (by JS) at a later
date. Within 5 days of the end of treatment, a test of cure
(TOC) lymph node aspiration was performed. The quality of
a random sample of the slides was controlled by the Depart-
ment of Biomedical Research of the Royal Tropical Institute,
Amsterdam.
Patients who had received any treatment for kala-azar in
the past were excluded. Nomadic patients, in whom follow up
would be impossible, were excluded. Informed written con-
sent was given by the patient or their guardian/parent.
Participation in the study was voluntary, and those who did
not participate were treated with Pentostam. Patients were
not excluded from treatment on the basis of severe disease.
We calculated that, at a power of 90% and a signiﬁcance
level of P 5 0.05 (two-tailed), to detect a difference of 10% in
cure, death, or relapse rate between the two groups, a sample
size of 207 patients in each arm was required. All consecutive
kala-azar patients newly diagnosed from 30 November until
31 December 1998 were alternately assigned to either the
Pentostam or the generic SSG treatment group. Allocation
was on the basis of the DAT registration number, noted in a
single ledger, with the number being allocated prior to enrol-
ment in the study. Patients with odd DAT numbers received
Pentostam, those with even numbers received generic SSG.
The study was not blinded. Volume and colour of the drug
was equal. The injection nurse knew which drug to give by
colour coding of the patient treatment card. Nurses were
trained and supervised in ﬁlling in the registration forms.
Data collection
The following data were collected at admission or soon there-
after: name, age, sex, address, previous treatment with penta-
valent antimony compound, height, weight, spleen size (in
cm, measured in the anterior axillary line to the furthest
point during quiet breathing), liver size (in cm, measured in
midclavicular line during quiet breathing), haemoglobin
(Hb), walking status (normal, with assistance, carried on
stretcher), DAT result (number, titre, and date tested) and
parasitology result (tissue, parasite density, date). During
treatment intermittent events and complications were noted
daily. The signs and symptoms associated with death were
recorded. At discharge, spleen size, liver size, Hb, weight,
post kala-azar dermal leishmaniasis (PKDL), TOC aspirate
(parasitology result, tissue, grade), and location of the chief
for the next 6 months were noted. Six months after discharge
we recorded history of fever, clinical symptoms, spleen size
and PKDL. An aspiration was only performed in case of clin-
ical features suggestive of a relapse.
Treatment
Treatment was given according to routine WHO and MSF
schedules: 20 mg/kg/day for 30 days of either Pentostam or
generic SSG intramuscularly. Both are colourless liquids, 1 mL
contains 100 mg pentavalent antimony. The minimum dose
was 2 mL (200 mg), no maximum upper limit was used. For
injecting volumes . 10 mL, the injection was given in two
halves, in each buttock. All patients, whether in the study or
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not, received free treatment and food. Intermittent illnesses
were treated according to the standard protocols. Mal-
nourished patients received supplemental or therapeutic feed-
ing according to severity.
Outcome variables
Initial cure at discharge, death during treatment, relapse and
ﬁnal cure (at 6 months after discharge) were the main out-
come parameters. A patient was considered initially cured if
clinically well at discharge and after at least 28 days of injec-
tions. If the TOC aspirate was positive, the patient continued
treatment with the same drug and weekly TOCs were done
until 2 consecutive TOCs were negative.
All patients were asked to return immediately, if any signs
were experienced, to exclude relapse and to return for a stan-
dard clinical follow-up after 6 months. Aspiration was done
only in case of symptoms suggestive for relapse (WHO 1996).
Travel expenses were paid and a bednet was given as an incen-
tive. If no relapse occurred within 6 months of discharge, the
patient was considered cured. The clinical assessment at
6 months follow-up was made without knowledge of the
treatment group.
Statistical analysis
Data were analysed with Excel (Microsoft) and Arcus-Quick
stat. For parametric data, we used the Z score test for com-
parison of means was used; for nonparametric data, the
Mann Whitney test; for categorical data, the x
2 test for trend.
Results
Patients
During the trial period 978 clinically suspected cases were
assessed; 516 were conﬁrmed as kala-azar and entered in the
trial (Figure 1). All 516 patients had been DAT-tested: 440
patients had a (high-titre) positive DAT result (85.6%) and
the DAT results of two patients were missing, but both were
parasitologically conﬁrmed by lymph node aspirate. 189
patients underwent aspiration; 140 had a positive aspirate







271 Pentostam 245 generic SSG
254 initial cure 239 initial cure
219 final cure 210 final cure
Figure 1 Flow chart describing the progress of patients through the
randomised trial.




Mean Median Mean Median P-value
Age (years) 012.5 009 012.2 010 0.90
Sex (m/f) 160/111 150/95 0.68 *
Duration of illness (months) 001.6 001 001.4 001 0.59
Ability to walk walking/stick/stretcher 229/3/18 216/4/15 0.85 †
Weight (kg) 026.6 021 027.0 021.7 0.61
Height (cm) 129.1 130.1 131.7 130.9 0.68
Hb (g/dl) 007.9 008 008.2 008.2 0.021 ‡
BMI (kg/m
2) 016.0 016.4 016.6  016.3 0.69
(in adults) (n 5 81) (n 5 66)
Spleen size (cm) 006.1 006 006.6 007 0.12
Weight for height 080.0  079.5 080.2  080 0.73
(in children) (n 5 188) (n 5 179)
Test used: Mann Whitney; except: *x
2, †x
2 for trend, ‡Z score comparison of the means.Tropical Medicine and International Health volume 5 no 5 pp 312–317 may 2000
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aspirate). 185 aspirations were taken from inguinal lymph
nodes, 4 from the spleen.
During the time of the study, 26 conﬁrmed kala-azar
patients did not ﬁt the entry criteria and were treated out-
side the study. The reasons were previous treatment for kala-
azar and nomadic lifestyle (no follow-up possible); no
eligible adult patients, or guardians of eligible children
refused to consent. 271 patients were assigned to receive
Pentostam and 245 generic SSG. A review of drug allocation
vs. DAT number showed none of the patients had been in-
correctly allocated.
Base-line patient characteristics
Except for Hb, which was lower in the Pentostam group
(Table 1), there were no signiﬁcant differences between the
two groups in base-line characteristics (age, sex, duration
of illness, ability to walk, spleen size, weight, height, body
mass index (BMI)(calculated for patients aged 16 years or
older), weight-for-height (calculated for patients aged under
16 years). The patients had a range of disease severity, but
many were in an advanced state of malnutrition and weak-
ness. The true severity of malnutrition is worse than indi-
cated by BMI and weight-for-height, because the weight of
some patients includes the weight of oedema ﬂuid and
ascites.
Outcome
The initial outcome is presented in Table 2. The initial cure
rate for the two treatment groups was 93.7 for Pentostam and
97.6% for generic SSG. Most had a negative TOC after treat-
ment. In the Pentostam group 5.9% needed an extension of
treatment due to a positive TOC at the end of treatment. In
the SSG group this was necessary in 5.3% of the patients. In
each group 2 patients were successfully treated with a sched-
ule of longer duration due to PKDL.
The main causes of the 22 deaths (16 Pentostam, 6 generic
SSG) were: anaemia and bleeding (Pentostam 5, generic SSG
3); gastro-enteritis (Pentostam 3, generic SSG 1); severe
vomiting (Pentostam 3, generic SSG 1). The remaining deaths
each occurred in one patient only and were, in the Pentostam
group: severe kwashiorkor and sepsis; liver failure and pneu-
monia; febrile illness of unknown origin; coma; unknown;
and in the generic SSG group: meningitis. There was no dif-
ference in death rates between patients treated in the two
Table 2 Initial outcome of 516 Sudanese patients with kala-azar who were treated either with Pentostam or generic SSG
Pentostam Generic SSG
———————––– ——————–––– Relative risk (95% 
no (%) no (%) P-value conﬁdence intervals)
Deaths during treatment 016 0(5.9) 006 0(2.4) 0.08 0.41 (0.16–1.04)
Initially cured: 254 (93.7) 239 (97.6)
Negative 1st TOC 236 (87.1) 224 (91.4) 0.15 1.05 (0.99–1.11)
Positive 1st TOC; treatment  016 0(5.9) 013 0(5.3) 0.92 0.90 (0.44–1.83)
extended until TOC negative
Negative TOC; treatment extended  002 0(0.7) 002 0(0.8) 1.0* –
because of PKDL during treatment
Defaulters 001 0(0.4) – 1.0*
Total 271 245 – –
Test used: x
2; except: *-Fisher exact two-tailed.
Relative risk
(95% conﬁdence
Pentostam Generic SSG P-value intervals)
Diarrhoea 41.7% 37.7% 0.40 0.90 (0.73–1.12)
Vomiting 41.0% 33.5% 0.10 0.82 (0.65–1.03)
Respiratory tract infection 43.9% 41.8% 0.64 0.95 (0.78–1.16)
Bleeding 11.9% 16.8% 0.14 1.42 (0.92–2.18)
Test used: x
2.
Table 3 Comparison of the frequency of
intercurrent events among 516 Sudanese
patients with kala-azar treated with
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different treatment centres Um Kuraa (15 of 374) and Kassab
(7 of 142), P 5 0.83.
There was no statistically signiﬁcant difference between the
two groups for the following changes during treatment:
increase of Hb (Pentostam 2.1 g/dL; generic SSG 2.0 g/dL);
increase in weight (Pentostam 2.1 kg; generic SSG 2.1 kg);
decrease in spleen size (Pentostam 5.1 cm; generic SSG 5.4).
The frequency of intercurrent events (diarrhoea, vomiting,
bleeding and respiratory tract infections) is shown in Table 3.
Follow-up
The ﬁnal outcome of those patients who were discharged
alive, and who could be traced for follow-up at 6 months is
summarized in Table 4. In total 437 (88.5%) of the surviving
patients were followed up, either through clinical examin-
ation (82.0%) or history of their well-being taken from a
family member (5.7%). There were 4 relapses, 4 deaths, and
33 cases of severe PKDL (grade 2 and 3) after discharge. The
ﬁnal cure rate, calculated for all patients minus those who
could not be traced for follow-up, was 91.3% (Pentostam)
and 95.9% (generic SSG). There were no signiﬁcant differ-
ences between treatment groups.
Discussion
This is the largest randomised drug evaluation ever under-
taken in kala-azar patients. The study was done in remote
areas under basic conditions: the treatment centres consisted
mainly of shelters built of mud and grass. Investigations
available to diagnose and treat complications were restricted
to urine microscopy and dipstick, colourometric Hb esti-
mation, and slides for malaria and Leishmania. Random-
ization by DAT ledger number produced two comparable
groups. The study could not be blinded due to the fact that
the drugs were in different types of vials. However, our main
outcome parameter, death, is not susceptible to information
bias, and does not require blinding. Although the patients
could learn which drug they received, the volume and colour
of the drugs given was equal, and neither patients nor nurses
expressed a preference of one drug over another during the
study. The nurses were trained and had ample experience in
treating kala-azar patients; they knew which of the two treat-
ments was given. Empty ampoules were collected to double
check that the right drugs were prescribed.
We followed the routine MSF kala-azar diagnostic schedule
for a high patient load during an epidemic, in agreement with
WHO guidelines for ﬁeld situations (WHO 1996).
Accordingly, in patients fulﬁlling the case deﬁnition, kala-
azar was conﬁrmed either by a strongly positive DAT titre
(and subsequent response to antimonial treatment), or a
positive aspirate. Diagnostic aspirations were taken from an
inguinal lymph node by paramedical staff. Few diagnostic
spleen aspirates were needed. The high number of children in
the study (mean age 12 years) is caused by the location within
a known endemic focus of kala-azar.
Although the difference in the number of deaths during
treatment between the two groups was not statistically signiﬁ-
cant, deaths among the Pentostam recipients (16) were more
than twice as frequent as those among the generic SSG group
(6). We have no explanation for this, but saw a similar trend
in our smaller, hospital-based study in Kenya (4) (Moore et
al. 2000). At 6 months follow-up we were able to locate 82%
of patients and examine them clinically. For another 5.7% we
obtained a history from relatives or their village chief of the
patient being well. Relapses, severe PKDL and death after dis-
Table 4 Final outcome of 516 Sudanese patients with kala-azar, treated with Pentostam or generic SSG, as assessed 6 months after discharge
Pentostam Generic SSG Total
——————— ——————— ———————
no (%) no (%) no (%) P-value
Number treated 271 245 516
Died during treatment 016 0(5.9) 006 0(2.4) 022 0(4.3) 0.08
Survived treatment, eligible for follow up 255 (94.1) 239 (97.6) 494 (95.7)
Not traced 031 (12.2) 026 (10.9) 057 (11.5) 0.76
Followed up at 6 months: 224 (87.8) 213 (89.1) 437 (88.5) 0.76
Clinical examination 206 (80.8) 199 (83.3) 405 (82.0) 0.55
History by close relative or chief 016 0(6.3) 012 0(5.0) 028 0(5.7) 0.68
Died after discharge 002 0(0.8) 002 0(0.8) 004 0(0.8) 1.00*
Relapse 003/224 0(1.3) 001/213 0(0.5) 004/437 0(0.9) 0.62*
Severe PKDL 021/224 0(9.4) 012/213 0(5.6) 033/437 0(7.6) 0.19
Total deaths 018/240 0(7.5) 008/219 0(3.7) 026/459 0(5.7) 0.11
Final cure rate 219/240 (91.3) 210/219 (95.9) 429/459 (93.5) 0.07
Test used: x
2; except: *Fisher exact two-tailed.Tropical Medicine and International Health volume 5 no 5 pp 312–317 may 2000
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Dispensary Association in Amsterdam for quality testing of
the generic SSG; to the Federal Ministry of Health of The
Sudan (Dr Mohamed Osman Abdelaziz El Gimiabi, Dr
Ahmed El Tigani El Mardi, and Dr Osman Sadig Bukhari)
for their support of the study; and to Regional Health
Authorities in Gedaref.
References
Moore E, O’Flaherty D, Heuvelmans H et al. (2000) A randomised
comparison of generic sodium stibogluconate (sodium antimony
gluconate, Albert David Ltd., Calcutta) and Pentostam (Glaxo
Wellcome, London) for the Treatment of Visceral Leishmaniasis In
Kenya. Bulletin of WHO, in press.
Seaman J, Pryce D, Sondorp E, Moody A, Bryceson ADM &
Davidson RN (1993) Epidemic visceral leishmaniasis in Sudan: a
randomised trial of aminosidine plus sodium stibogluconate versus
sodium stibogluconate alone. Journal of Infectious Disease 168,
715–720.
Seaman J, Mercer A & Sondorp E (1996a) The epidemic of visceral
leishmaniasis in Western Upper Nile, Southern Sudan: course and
impact from 1984 to 1994. International Journal of Epidemiology
25, 862–871.
Seaman J, Mercer A, Sondorp E & Herwaldt B (1996b) Epidemic
visceral leishmaniasis in Southern Sudan: treatment of severely
debilitated patients under wartime conditions with limited
resources. Annals of Internal Medicine 124, 664–672.
Sundar S, Sinha PR, Agrawal NK et al. (1998) A cluster of cases of
severe cardiotoxicity among kala-azar patients treated with a high-
osmolarity lot of sodium antimony gluconate. American Journal
of Tropical Medicine and Hygiene 59, 139–143.
UNDP/World Bank/WHO (1997) Progress 1995–96: 13th program
report of the UNDP/World Bank/WHO special program for
research and training in tropical diseases. World Health
Organization, Geneva.
WHO (1996) Manual on Visceral Leishmaniasis Control. World
Health Organization, Geneva.
© 2000 Blackwell Science Ltd 317
charge were infrequent, and equally distributed between the
two groups. The 57 patients who could not be traced during
the follow-up were excluded from the calculations of ﬁnal
cure and ﬁnal death rates. Reasons for failed follow-up were
moved to another state (Sennar) or inaccessibility (road con-
ditions). It is reasonable to assume that their ﬁnal outcome
will not be different from those who could be traced. The
ﬁnal cure rate includes one defaulter (a child who received 18
injections) who was clinically investigated after 6 months and
considered cured.
The ﬁnal death rate in the study was 5.7%. This is lower
than the death rate among patients treated during the epidemic
in south Sudan, where 11% died (Seaman et al. 1996b), but
similar to the 6% mortality we found during an evaluation of
treatment with Pentostam with or without aminosidine in
south Sudan (Seaman et al. 1993). None of the deaths had the
clinical features of cardiac arrythmias, which have been consid-
ered by others (Sundar et al. 1998) to be the cause of unex-
pected deaths during treatment with antimonials.
We conclude that generic SSG (as manufactured by Albert
David and quality tested by IDA) can be used safely and
routinely for the treatment of kala-azar patients. Generic SSG
costs only 1/14 of the price of Pentostam. The use of generic
SSG may make treatment of kala-azar affordable for national
governments. However, we add a note of caution: production
of antimonials is notorious for its batch-to-batch variation.
Continuous quality control of each batch produced is essen-
tial to guarantee safe treatment. At present, despite its high
price, we ﬁnd that Pentostam is sometimes available infor-
mally in East Africa, and used in inadequate doses and dur-
ation by the villagers themselves. The availability of cheaper
sodium stibogluconate could increase unregulated self-
medication with inadequate regimens. Eventually, this might
lead to antimonial-resistant leishmaniasis. We therefore hope
to continue our ﬁeld evaluations of antileishmanial drugs
such as aminosidine and miltefosine, to identify affordable
second-line treatment for kala-azar in Africa.
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